Xiajie Shi1,2, Gan Huang1,2, Yanfei Wang1,2, Zhenqi Liu3, Chao Deng1,2, Xia Li1,2, Peilin Zheng4,5, Zhiguang Zhou6,7. 1. Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. 2. Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China. 3. Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA. 4. Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. peilinz@csu.edu.cn. 5. Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China. peilinz@csu.edu.cn. 6. Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. zhouzhiguang@csu.edu.cn. 7. Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China. zhouzhiguang@csu.edu.cn.
Abstract
AIMS/HYPOTHESIS: The aim of this work was to investigate whether tetraspanin 7 autoantibodies (TSPAN7A) are valuable in predicting poor beta cell function in individuals with latent autoimmune diabetes in adults (LADA). METHODS: The cross-sectional study involved participants with LADA (n = 173), type 1 diabetes (n = 158), type 2 diabetes (n = 204) and healthy control participants (n = 170). The longitudinal study involved 53 participants with LADA, with a 3-year follow-up. In both cohorts, TSPAN7A in the sera were measured by a luciferase immunoprecipitation system assay, and physical and clinical characteristics were recorded. RESULTS: The prevalence of TSPAN7A in LADA, type 1 diabetes, type 2 diabetes and healthy control participants was 21.4% (37/173), 26% (41/158), 0.5% (1/204) and 1.2% (2/170), respectively. Importantly, measurement of TSPAN7A significantly increased the number of individuals with LADA found to be positive for multiple antibodies (32.4% vs 22%; p < 0.001). Further logistic regression analysis demonstrated that positivity for TSPAN7A (OR 2.87, p = 0.034), disease duration (OR 1.83, p = 0.019) and GAD antibody titre (OR 2.67, p = 0.009) were risk factors for beta cell function in LADA, while BMI (OR 0.34, p = 0.001) was a protective factor. In the prospective study in individuals with LADA, the median annual decrease in rates of fasting C-peptide and 2 h postprandial C-peptide in individuals who were positive for TSPAN7A was significantly higher when compared with the decrease in those who were negative for TSPAN7A (34.6% vs 7.9%, p = 0.043 and 33.2% vs 11%, p = 0.041, respectively). CONCLUSIONS/ INTERPRETATION: TSPAN7A are valid islet autoantibodies for use in East Asian populations with autoimmune diabetes and can discriminate individuals with LADA who have lower beta cell function after disease progression.
AIMS/HYPOTHESIS: The aim of this work was to investigate whether tetraspanin 7 autoantibodies (TSPAN7A) are valuable in predicting poor beta cell function in individuals with latent autoimmune diabetes in adults (LADA). METHODS: The cross-sectional study involved participants with LADA (n = 173), type 1 diabetes (n = 158), type 2 diabetes (n = 204) and healthy control participants (n = 170). The longitudinal study involved 53 participants with LADA, with a 3-year follow-up. In both cohorts, TSPAN7A in the sera were measured by a luciferase immunoprecipitation system assay, and physical and clinical characteristics were recorded. RESULTS: The prevalence of TSPAN7A in LADA, type 1 diabetes, type 2 diabetes and healthy control participants was 21.4% (37/173), 26% (41/158), 0.5% (1/204) and 1.2% (2/170), respectively. Importantly, measurement of TSPAN7A significantly increased the number of individuals with LADA found to be positive for multiple antibodies (32.4% vs 22%; p < 0.001). Further logistic regression analysis demonstrated that positivity for TSPAN7A (OR 2.87, p = 0.034), disease duration (OR 1.83, p = 0.019) and GAD antibody titre (OR 2.67, p = 0.009) were risk factors for beta cell function in LADA, while BMI (OR 0.34, p = 0.001) was a protective factor. In the prospective study in individuals with LADA, the median annual decrease in rates of fasting C-peptide and 2 h postprandial C-peptide in individuals who were positive for TSPAN7A was significantly higher when compared with the decrease in those who were negative for TSPAN7A (34.6% vs 7.9%, p = 0.043 and 33.2% vs 11%, p = 0.041, respectively). CONCLUSIONS/ INTERPRETATION: TSPAN7A are valid islet autoantibodies for use in East Asian populations with autoimmune diabetes and can discriminate individuals with LADA who have lower beta cell function after disease progression.
Entities:
Keywords:
Beta cell function; Islet autoantibodies; Latent autoimmune diabetes in adults; Tetraspanin 7; Type 1 diabetes
Authors: Jeffrey P Krischer; Kristian F Lynch; Desmond A Schatz; Jorma Ilonen; Åke Lernmark; William A Hagopian; Marian J Rewers; Jin-Xiong She; Olli G Simell; Jorma Toppari; Anette-G Ziegler; Beena Akolkar; Ezio Bonifacio Journal: Diabetologia Date: 2015-02-10 Impact factor: 10.122
Authors: H J Aanstoot; S M Kang; J Kim; L A Lindsay; U Roll; M Knip; M Atkinson; P Mose-Larsen; S Fey; J Ludvigsson; L Landin; J Bruining; N Maclaren; H K Akerblom; S Baekkeskov Journal: J Clin Invest Date: 1996-06-15 Impact factor: 14.808
Authors: F Winnock; M R Christie; M R Batstra; H J Aanstoot; I Weets; K Decochez; P Jopart; D Nicolaij; F K Gorus Journal: Diabetes Care Date: 2001-07 Impact factor: 19.112
Authors: Peter D Burbelo; Hiroki Hirai; Alexandra T Issa; Albert Kingman; Ake Lernmark; Sten-A Ivarsson; Abner L Notkins; Michael J Iadarola Journal: Diabetes Care Date: 2010-01-19 Impact factor: 17.152
Authors: Kerry A McLaughlin; Carolyn C Richardson; Aarthi Ravishankar; Cristina Brigatti; Daniela Liberati; Vito Lampasona; Lorenzo Piemonti; Diana Morgan; Richard G Feltbower; Michael R Christie Journal: Diabetes Date: 2016-03-07 Impact factor: 9.461
Authors: Matthew T Dickerson; Prasanna K Dadi; Regan B Butterworth; Arya Y Nakhe; Sarah M Graff; Karolina E Zaborska; Charles M Schaub; David A Jacobson Journal: J Physiol Date: 2020-09-01 Impact factor: 5.182